RU2003120798A - Новые производные n-(фенилсульфонил) глицина и их применение в терапии - Google Patents

Новые производные n-(фенилсульфонил) глицина и их применение в терапии

Info

Publication number
RU2003120798A
RU2003120798A RU2003120798/04A RU2003120798A RU2003120798A RU 2003120798 A RU2003120798 A RU 2003120798A RU 2003120798/04 A RU2003120798/04 A RU 2003120798/04A RU 2003120798 A RU2003120798 A RU 2003120798A RU 2003120798 A RU2003120798 A RU 2003120798A
Authority
RU
Russia
Prior art keywords
group
hydrogen atom
amino
compound according
phenyl
Prior art date
Application number
RU2003120798/04A
Other languages
English (en)
Inventor
Мартин БАРТ (FR)
Мартин Барт
Мишель БОНДУ (FR)
Мишель Бонду
Кристоф МАТТ (FR)
Кристоф МАТТ
Пьер ДОДЕЙ (FR)
Пьер Додей
Жан-Мишель ЛУККАРИНИ (FR)
Жан-Мишель Луккарини
Жан-Люк ПАКЕТ (FR)
Жан-Люк ПАКЕТ
Дидье ПРЮНЁ (FR)
Дидье ПРЮНЁ
Original Assignee
Лаборатуар Фурнье Са (Fr)
Лаборатуар Фурнье Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Фурнье Са (Fr), Лаборатуар Фурнье Са filed Critical Лаборатуар Фурнье Са (Fr)
Publication of RU2003120798A publication Critical patent/RU2003120798A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (12)

1. Соединение N-(фенилсульфонил) глицина, отличающееся тем, что оно выбрано из группы, состоящей из
i) соединений, описываемых формулой:
Figure 00000001
в которой
W представляет собой атом хлора,
Х представляет собой атом водорода, метильную группу или атом хлора,
Y и Z представляют собой, каждый независимо от другого, атом водорода или атом хлора, или:
Х и W или Х и Y образуют совместно с атомами углерода, к которым они присоединены, фенильное ядро,
R представляет собой атом водорода, аллильную группу или C1-C4 алкильную группу, незамещенную или замещенную фенильной группой, метоксигруппой, пиридинильной группой, карбоксамидной или N-метилкарбоксамидной группой,
r1 представляет собой атом водорода, C1-C4 алкильную группу или группу (CH2)m-R’2,
n и m представляют собой, каждый независимо от другого, 1, 2, 3 или 4,
R2 и R’2 представляют собой, каждый независимо от другого, группу
Figure 00000002
группу
Figure 00000003
группу
Figure 00000004
группу
Figure 00000005
группу
Figure 00000006
группу
Figure 00000007
группу
Figure 00000008
или
группу
Figure 00000009
r3 представляет собой атом водорода или C1-C4 алкильную группу,
R4 представляет собой атом водорода, группу СОСН3, группу СООСН3 или C1-C4 алкильную группу,
r5 представляет собой атом водорода или C1-C4 алкильную группу, незамещенную или замещенную фенильной группой,
R6 представляет собой атом водорода или группу CONHC2H5,
R7 представляет собой атом водорода,
группу
Figure 00000010
группу
Figure 00000011
группу
Figure 00000012
группу
Figure 00000013
или
группу CONHCH3
r8 представляет собой атом водорода, группу NH2 или C1-C4 алкильную группу, p равно 4, 5 или 6;
ii) соли замещения соединений, соответствующих формуле I, образованных в результате их реакции с кислотой.
2. Соединение по п.1, отличающееся тем, что R представляет собой фенилметильную группу.
3. Соединение по п.1, отличающееся тем, что R представляет собой C1-C4 алкильную группу.
4. Соединение по любому из пунктов с 1 по 3, отличающееся тем, что:
r1 представляет собой атом водорода, C1-C4 алкильную группу или группу (CH2)m-R’2
m представляет собой 1, 2, 3 или 4,
R’2 представляет собой
группу
Figure 00000014
группу
Figure 00000015
группу
Figure 00000016
группу
Figure 00000017
группу
Figure 00000018
или
группу
Figure 00000019
R3 представляет собой атом водорода или C1-C4 алкильную группу,
R4 представляет собой атом водорода, группу СОСН3, группу СООСН3 или C1-C4 алкильную группу,
r5 представляет собой атом водорода или C1-C4 алкильную группу, которая может быть замещена фенильной группой,
R6 представляет собой атом водорода или группу CONHC2H5,
R8 представляет собой атом водорода,
p равно 4, 5 или 6.
5. Соединение по любому из пунктов с 1 по 4, отличающееся тем, что:
R2, представляет собой группу
Figure 00000020
группу
Figure 00000021
группу
Figure 00000022
группу
Figure 00000023
или
группу
Figure 00000024
R3 представляет собой атом водорода
R4 представляет собой атом водорода или C1-C4 алкильную группу, предпочтительно метильную,
R5 представляет собой атом водорода или C1-C4 алкильную группу, предпочтительно метильную,
R7 представляет собой атом водорода,
группу
Figure 00000025
группу
Figure 00000026
группу
Figure 00000027
группу
Figure 00000028
или
группу CONHCH3
R8 представляет собой атом водорода или группу NH2.
6. Соединение по любому из пунктов с 1 по 5, отличающееся тем, что R1 или R2 включают в свою структуру амидинильную группу.
7. Соединение по п.6, отличающееся тем, что R2 представляет собой фениламидиновую группу.
8. Соединение по п.6, отличающееся тем, что R2 включает в себя 2-имидазолильную группу.
9. Соединение по пунктам с 1 по 5, отличающееся тем, что оно выбрано из группы, включающей следующие соединения:
N-[2-[[[4-(аминоиминометил)фенил]метил][4-(1-пирролидинил)бутил]амино]-2-оксоэтил]-2-[[(2,4-дихлор-3-метилфенил)сульфонил](2-фенилэтил)амино]ацетамида дигидрохлорид,
N-[2-[[[4-(аминоиминометил)фенил]метил][3-(диметиламино)пропил]амино]-2-оксоэтил]-2-[[(2,4-дихлор-3-метилфенил)сульфонил](2-фенилэтил)амино]ацетамида дигидрохлорид,
N-[2-[[[4-(аминоиминометил)фенил]метил](4-пиперидинилэтил)амино]-2-оксоэтил]-2-[[(2,4-дихлор-3-метилфенил)сульфонил](2фенилэтил)амино]ацетамидабис-трифторацетат,
N-[2-[(4-аминобутил)(4-пиперидинилметил)амино]-2-оксоэтил]-2-[[(2,4-дихлор-3-метилфенил)сульфонил](2-фенилэтил)амино]ацетамида бис-трифторацетат,
2-[[(2,4-дихлор-3-метилфенил)сульфонил](2-фенилэтил)амино]-N-[2-[[[4-(4,5-дигидро-1H-имидазол-2-ил)фенил]метил][3-(диметиламино)пропил]амино]-2-оксоэтил]ацетамида дигидрохлорид,
2-[[(2,4-дихлор-3-метилфенил)сульфонил]метиламино]-N-[2-[[[4-(4,5-дигидро-1Н-имидазол-2-ил)фенил]метил]метиламино]-2-оксоэтил]ацетамида гидрохлорид,
2-[[(2,4-дихлор-3-метилфенил)сульфонил](2-фенилэтил)амино]-N-[2-[[3-(1Н-имидазол-5-ил)пропил][4-(1-пиррол идинил)бутил]амино]-2-оксоэтил]ацетамида дигидрохлорид.
10. Фармацевтическая композиция, отличающаяся тем, что она включает в сочетании, по меньшей мере, с одним физиологически приемлемым наполнителем по меньшей мере, одно соединение, соответствующее формуле I, по любому из пунктов с 1 по 9, или его соль замещения кислотой.
11. Применение соединения, соответствующего формуле I, по любому из пунктов с 1 по 9, или его соли замещения кислотой, для приготовления лекарственного средства, предназначенного для лечения боли.
12. Применение соединения, соответствующего формуле I, по любому из пунктов с 1 по 9, или его соли замещения кислотой, для приготовления лекарственного средства, предназначенного для лечения воспалительных заболеваний.
RU2003120798/04A 2001-01-08 2002-01-07 Новые производные n-(фенилсульфонил) глицина и их применение в терапии RU2003120798A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100195A FR2819254B1 (fr) 2001-01-08 2001-01-08 Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR01/00195 2001-01-08

Publications (1)

Publication Number Publication Date
RU2003120798A true RU2003120798A (ru) 2004-12-27

Family

ID=8858600

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003120798/04A RU2003120798A (ru) 2001-01-08 2002-01-07 Новые производные n-(фенилсульфонил) глицина и их применение в терапии

Country Status (17)

Country Link
US (1) US20040063725A1 (ru)
EP (1) EP1351928A2 (ru)
JP (1) JP2004534729A (ru)
KR (1) KR20030070080A (ru)
CN (1) CN1484633A (ru)
BR (1) BR0206159A (ru)
CA (1) CA2434124A1 (ru)
CZ (1) CZ20031715A3 (ru)
FR (1) FR2819254B1 (ru)
HU (1) HUP0402507A2 (ru)
IL (1) IL156565A0 (ru)
MX (1) MXPA03006093A (ru)
NO (1) NO20033099L (ru)
PL (1) PL365219A1 (ru)
RU (1) RU2003120798A (ru)
SK (1) SK8282003A3 (ru)
WO (1) WO2002053516A2 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP59808A (en) * 2001-02-24 2011-05-10 Boehringer Ingelheim Pharma Xanthine derivative, production and use thereof as a medicament
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0408689B8 (pt) 2003-03-25 2021-05-25 Laboratoires Fournier S A derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
WO2009021758A1 (de) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamide mit analgetischer wirkung
US8394805B2 (en) * 2007-08-14 2013-03-12 Boehringer Ingelheim International Gmbh Compounds
EP2025673A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2025675A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2025668A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2212281B1 (de) * 2007-08-14 2011-03-23 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer wirkung
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103965050B (zh) * 2013-02-01 2015-09-30 清华大学 一种卤代芳环类化合物及其制备方法
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508444A1 (fr) * 1981-06-29 1982-12-31 Irceba Nouveaux derives sulfonyle du tryptophane utiles en tant que medicaments et leur procede de preparation
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5714497A (en) * 1993-02-15 1998-02-03 Sanofi Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
FR2735128B1 (fr) * 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2756562B1 (fr) * 1996-12-04 1999-01-08 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2765222B1 (fr) * 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES

Also Published As

Publication number Publication date
CN1484633A (zh) 2004-03-24
JP2004534729A (ja) 2004-11-18
MXPA03006093A (es) 2005-02-14
EP1351928A2 (fr) 2003-10-15
FR2819254A1 (fr) 2002-07-12
WO2002053516A2 (fr) 2002-07-11
FR2819254B1 (fr) 2003-04-18
CA2434124A1 (fr) 2002-07-11
IL156565A0 (en) 2004-01-04
WO2002053516A3 (fr) 2002-10-10
KR20030070080A (ko) 2003-08-27
NO20033099D0 (no) 2003-07-07
CZ20031715A3 (cs) 2003-11-12
US20040063725A1 (en) 2004-04-01
SK8282003A3 (en) 2003-12-02
BR0206159A (pt) 2003-12-23
HUP0402507A2 (hu) 2005-03-29
PL365219A1 (en) 2004-12-27
NO20033099L (no) 2003-09-02

Similar Documents

Publication Publication Date Title
RU2003120798A (ru) Новые производные n-(фенилсульфонил) глицина и их применение в терапии
RU2203887C2 (ru) Циклические аминопроизводные, фармацевтическая композиция и способ профилактики заболевания
RU2214997C2 (ru) Производные адамантана, способ их получения, фармацевтическая композиция и способ получения фармацевтической композиции
RU2006116886A (ru) Производные n-[фенил(алкилпиперидин-2-ил]бензамида, их получение и их применение в терапии
RU96104356A (ru) Производные амидина, обладающие активностью против синтетазы оксида азота (у)
RU2000117574A (ru) Производные адамантана
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
CA2458035A1 (en) Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
KR910016765A (ko) 아세트산 유도체
RU2005123802A (ru) Производные адамантана, способы их получения и содержащие их фармацевтические композиции
JP2008509166A5 (ru)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
HUP0201646A2 (hu) Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
RU99105119A (ru) Производные пурина и их применение в качестве антикоагулянтов
RU2008106058A (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
RU2007111758A (ru) Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ
JP2005522480A5 (ru)
RU2001113733A (ru) N-(2-арилпропионил) сульфонамиды и содержащие их фармацевтические препараты
RU98120057A (ru) Производные d-пролина
RU2007121219A (ru) Диазациклоалканы как агонисты окситоцина
JP2008519783A5 (ru)
RU2001103646A (ru) Производные 2-аминопиридинов, их использование в качестве лекарственных средств и содержащие их фармацевтические композиции
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof
KR960701007A (ko) 피롤-아미딘계 화합물 및 약제학적으로 허용 가능한 그 염, 그 제조방법 및 상기 화합물을 포함하는 약제조성물

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20050324